A wide diversity of adeno-associated virus (AAV) structural proteins uncovered from latent
genomes in primate tissue has expanded the number of AAV vector serotypes, which can …

We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and
noninvasive gene transfer to the central and peripheral nervous systems. However, a …

Recombinant adeno-associated viruses (AAVs) are popular in vivo gene transfer vehicles.
However, vector doses needed to achieve therapeutic effect are high and some target …

Adeno-associated virus serotype 9 (AAV9)-mediated gene transfer has been reported in
central nervous system (CNS) and peripheral tissues. The current study compared the …

Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9)
to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that …

Several attempts have been made to discover the ideal vector for gene therapy in central
nervous system (CNS). Adeno-associated viruses (AAVs) are currently the preferred vehicle …

Recombinant adeno-associated virus (AAV) vectors effectively transfer and express foreign
genes in the brain. The transferred genes, however, are selectively expressed in neurons …

The ability of recombinant adeno-associated virus (AAV) to deliver transgenes to the CNS
has allowed for several advancements in the field of gene therapy to treat brain disorders …

Adeno-associated virus (AAV) vectors exhibit a number of properties that have made this
vector system an excellent choice for both CNS gene therapy and basic neurobiological …

Adeno-associated virus (AAV) is the most common vector for clinical gene therapy of the
CNS. This popularity originates from a high safety record and the longevity of transgene …